Novel Radioligand Therapy Shows Complete Response in Muscle-Invasive Bladder Cancer Patient
核心洞察
First-in-human data demonstrates complete response in a late-stage muscle-invasive bladder cancer (搜索) patient using Lu177-PentixaTher, a CXCR4 (搜索)-targeted radioligand therapy administered intravesically.
The innovative treatment approach combines neoadjuvant chemotherapy with targeted radiopharmaceutical therapy, showing potential for bladder preservation in MIBC (搜索) patients.
Pentixapharm (搜索)'s expanding clinical program includes over 100 patients treated with PentixaTher, with an ongoing Phase I/II trial in leukemia patients.
In a groundbreaking development for bladder cancer treatment, researchers will present the first-in-human data for a novel radioligand therapy at the American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2025) in San Francisco. The case study showcases a complete response in a late-stage muscle-invasive bladder cancer (搜索) (MIBC (搜索)) patient treated with Pentixapharm (搜索)'s Lu177-PentixaTher compound.
Treatment Approach and Clinical Response
The innovative treatment protocol combined three cycles of neoadjuvant combination chemotherapy with intravesical administration of the CXCR4 (搜索)-targeting radiopharmaceutical. Prior to treatment, Ga68-PentixaFor (搜索) PET/CT imaging confirmed intravesical CXCR4 expression, providing a rational basis for the targeted therapy approach.
Following Lu177-PentixaTher instillation, pathological examination post-transurethral resection revealed a complete response, suggesting significant potential for bladder preservation in MIBC (搜索) patients. The intravesical administration route represents a particular advantage, enabling localized treatment delivery with enhanced precision while minimizing systemic exposure and potential adverse effects.
Expanding Clinical Evidence
The successful case study adds to mounting evidence supporting CXCR4 (搜索) as a viable therapeutic target across multiple oncology indications. To date, Pentixapharm (搜索) has accumulated clinical experience with PentixaTher in over 100 patients, laying a strong foundation for their sponsored clinical development program.
Ongoing Clinical Development
Building on these promising results, Pentixapharm (搜索) has expanded its clinical program. In November 2024, the company initiated a Phase I/II trial in Nantes, France, investigating PentixaTher in patients with acute myeloid and lymphoblastic leukemia (搜索) (AML/ALL).
Dr. Ralph Wirtz will present the detailed findings at ASCO-GU 2025's Poster Session B on February 14, providing the medical community with comprehensive data on this novel therapeutic approach.